Article
Characterization of recombinant factor VIII and a recombinant factor VIII deletion mutant using a rabbit immunogenicity model system.
Blood - 15 Oct 1990
Esmon P C, Kuo H S, Fournel M A
Abstract excerpt
The use of factor VIII prepared genetically engineered cell lines (rFVIII) may avoid some of the problems inherently associated with administering plasma-derived factor VIII (pdFVIII) concentrates to hemophilia A patients. Although rFVIII may represent an improvement over traditional therapeutics, the chance exists that protein production in cell culture may result in the presence of novel epitopes that may...
Topics
- Animals
- Antibodies
- Antibodies, Monoclonal
- Binding, Competitive
- Blotting, Western
- Chromosome Deletion
- Enzyme-Linked Immunosorbent Assay
- Epitopes
- Factor VIII
- Glycosylation
- Immunosorbent Techniques